Biomarkers and Precision Medicine Community

 View Only

AAPSbutton2.png
If you're not a member of this community and would like to join it, click the orange Join button.

Leadership

Chair: Karen Quadrini  | Vice Chair: Stephanie Cape | Past Chair: Mohamed Hassanein | Secretary: TBD | Learning Opportunities Managers: Lakshmi Amaravadi, Carmen Fernandez-Metzler, Joel Mathews, Yan Ni, Alok Pandey, Iris Qiu, Karen Quadrini, Honglue (Holly) Shen, Jianing Zeng, Lindsay King, Jing Shi | Member Engagement Manager: Sasha Fraser, Amanda Hays, Jennifer Vance, Jad Zoghbi | Scientific Advisory Committee Regulatory Response Subcommittee Members: Robert (RJ) Neely, Joe Thomas

2025 Biomarkers and Precision Medicine Community Goals (PDF)

Latest Discussion Posts

Please login to see all eligible discussion postings.

Reach out to [email protected] if you need assistance.

Announcements

  • OSD onCAR-T: Preclinical Assessment of Potential for Secondary Malignancies - Clinical

    By: Carmen Fernandez-Metzler Carmen Fernandez-Metzler , 20 days ago

    📅 Date: Monday, June 16, 2025

    🕛 Time: 12:00 PM – 1:00 PM Eastern Time

    📍 Location: Virtual Seminar @ https://global.gotomeeting.com/join/271724949

    🧪 OSD Overview

    Join us for an engaging 1-hour discussion featuring:

    Dr. Gabriela Hernandez Hoyos (BMS) and Dr. Ilayaraja Muthuramu (J&J)
    Experts in genomic risk analysis and safety assessments of CAR T platforms

    They will explore:

    ●        Genomic risks in lentiviral vs. gene-edited CAR T products

    ●        Key molecular and functional assays used in risk assessment

    ●        Preclinical safety challenges in autologous vs. allogeneic approaches

    ●        Insights from published case studies and FDA-approved testing strategies

    🧠 Who Should Attend?

    Scientists, researchers, and professionals working in:
    - Gene and cell therapy
    - Regulatory science
    - Oncology R&D
    - Translational medicine

    🔗 Why Attend?

    - Hear from leaders in the field
    - Participate in an open discussion on safety assessment strategies
    - Gain insights into regulatory and translational approaches for CAR T therapies

    More

Latest Shared Files

Log in to see this information

Reach out to [email protected] if you need assistance.